Covid-19 vaccine

  • U.S. disease expert Fauci says vaccine verdict due by early December
    LONDON, October 25 (Reuters): U.S. infectious disease expert Anthony Fauci said on Sunday it would be clear whether a COVID-19 vaccine was safe and effective by early December, but that more widespread vaccination would not be likely until later in 2021. "We will know whether a vaccine is safe and effective by the end of November, the beginning of December," Fauci told the BBC. "When you talk about vaccinating a substantial proportion of the population, so tha
  • Russia receives renewed approval for COVID-19 vaccine trials in India: RDIF
    MOSCOW, October 17 (Reuters): The Russian Direct Investment Fund (RDIF) and Dr Reddy's Laboratories Ltd have received renewed approval to conduct late-stage clinical trials in India of the Russian COVID-19 vaccine, the sovereign wealth fund said on Saturday. Large-scale trials of the Sputnik V vaccine in India were first announced and then knocked back by Indian regulators, who said the scale of Phase I and II trials conducted in Russia earlier this year was too small, requ
  • Sinovac coronavirus vaccine offered by Chinese city for emergency use costs $60
    BEIJING, October 17 (Reuters): A Chinese city is offering Sinovac Biotech's <SVA.O> experimental COVID-19 vaccine to essential workers and other high-risk groups as part of a national programme for about $60. The eastern city of Jiaxing's center for disease control and prevention (CDC) said in a statement on WeChat that two doses of the vaccine candidate, called CoronaVac, will cost 200 yuan ($29.75) per dose and that vaccinations for key groups including medical
  • Sputnik V Covid-19 vaccine gets nod for clinical trials in India
    New Delhi, October 17 (IANS): The Drug Controller General of India (DCGI) has granted approval to Dr Reddy's, a global pharmaceutical company headquartered in India, to conduct phase 2 and 3 clinical human trials of the Sputnik V, a Covid-19 vaccine made by Russia. On September 16, the Russian Direct Investment Fund (RDIF) and Dr Reddy's Laboratories Limited had agreed to cooperate on clinical trials and distribution of Sputnik V Covid-19 vaccine in India. Sputnik V, an a
  • COVID-19 vaccine may be ready by year-end - WHO's Tedros
    GENEVA, October 6 (Reuters): A vaccine against COVID-19 may be ready by year-end, the head of the World Health Organization (WHO) said on Tuesday, without elaborating. WHO Director-General Tedros Adhanom Ghebreyesus called for solidarity and political commitment by all leaders to ensure equal distribution of vaccines when they become available. "We will need vaccines and there is hope that by the end of this year we may have a vaccine. There is hope," Tedros said i
  • China in talks with WHO over assessing its COVID-19 vaccines for global use
    SINGAPORE, October 6 (Reuters): China is in talks to have its locally-produced COVID-19 vaccines assessed by the World Health Organization, as a step toward making them available for international use, a WHO official said on Tuesday. Hundreds of thousands of essential workers and other groups considered at high risk in China have been given locally-developed vaccines even as clinical trials had not been fully completed, raising safety concerns among experts. Socorro Escalate
  • Aim to cover 25 cr with COVID vaccine by July: Vardhan
    New Delhi, October 4 (IANS): Union Health Minister Harsh Vardhan said on Sunday that the Centre is working on plans to procure 400-500 million doses of Covid-19 vaccine, which will be administered to up to 25 crore people by July 2021. "Government plans to receive and utilise 400-500 million Covid-19 vaccine doses. Our target is to cover 20-25 crore people by July 2021. For that, we are building capacities in HR, training, supervision, etc, on a massive scale," he said at
  • 20-25 cr to get 40-50 cr doses of Covid vaccine by July 2021: Govt
    New Delhi, October 4 (PTI): The Centre estimates to receive and utilise 40-50 crore doses of COVID-19 vaccine covering 20-25 crore people by July next year and it is preparing a format for the states to submit by October-end their list of priority population group to receive the vaccine, Union Health Minister Harsh Vardhan said on Sunday. He said priority would be given to health workers engaged in COVID-19 management in getting the vaccine. During an interaction with his social
  • COVID-19 vax to be rolled out within 3 months in UK: Report
    London, October 4 (IANS): The COVID-19 vaccine developed by scientists at the Oxford University, which is advanced stages of the trial, could be rolled out in as little as three months in the UK, a report said. According to the Times, a mass roll-out of a coronavirus vaccine could be completed in as little as three months, raising the prospect of every adult in the country receiving a jab as early as Easter. Scientists working on the Oxford vaccine hope it could be approved by re
  • COVID-19 vaccine roll-out expected in less than 3 months in UK - The Times
    October 3 (Reuters) - A mass roll-out of a COVID-19 vaccine in Britain could be finished in as little as three months, the Times reported, citing government scientists. Scientists working on the Oxford vaccine hope regulators approve it before the beginning of 2021, the newspaper said. A full COVID-19 immunization programme, which would exclude children, could be quicker than experts predicted, the Times said, adding that health officials estimate that every adult could receive a
  • Russian scientist behind COVID-19 vaccine defends 'wartime' roll-out
    MOSCOW, September 29 (Reuters): Russia plans to share preliminary results of its COVID-19 vaccine trial based on the first six weeks of monitoring participants, raising the tempo in an already frenzied global race to end the pandemic. Alexander Gintsburg, head of the Gamaleya Institute that produced the Sputnik V vaccine, told Reuters that the pace of its development was necessary under the "wartime" conditions of a pandemic but no corners were being cut. Russia ha
  • Serum Institute to manufacture 200mn doses of Covid-19 vaccine
    New Delhi, September 29 (IANS) A further collaboration among the Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, Gavi and the Bill and Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective Covid-19 vaccines for India and low-and middle income countries. This brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation
  • 'Does govt have Rs 80,000 cr for covid vaccine'
    Adar Poonawalla: Will Govt have 80,000 crores available over the next one year? New Delhi, September 26 (IANS): Rs 80,000 crore will be the cost of vaccinating everyone in India with the Covid-19 vaccine whenever it is available. Adar Poonawalla, the CEO of the Serum Institute of India (SII) on Saturday asked the Indian government whether Rs 80,000 crore will be available over the next one year to buy the Covid vaccine and distribute it to everyone. SII is the world's larg
  • J&J kicks off final study of single-shot COVID-19 vaccine in 60,000 volunteers
    CHICAGO, September 23 (Reuters): Johnson & Johnson on Wednesday kicked off a final 60,000-person trial of a single-shot COVID-19 vaccine that potentially would simplify distribution of millions of doses compared with leading rivals using two doses. The company expects results of the Phase III trial by year end or early next year, Dr. Paul Stoffels, J&J's chief scientific officer, said in a joint press conference with officials from the National Institutes of Health
  • Phase 3 trial of Oxford vaccine to begin in Pune from next week
    New Delh, September 19 (PTI): The Phase 3 human clinical trial of the COVID-19 vaccine developed by Oxford University and being manufactured by the Serum Institute of India (SII) will begin at the Sassoon General Hospital in Pune next week. Dean of the state-run Sassoon General Hospital Dr Muralidhar Tambe told this to PTI on Saturday. "The phase-III trial of 'Covishield' vaccine will begin at Sassoon hospital from next week. It is likely to start on Monday. Some vol
  • WHO says safety comes first as over 170 nations join COVID-19 vaccine plan
    SINGAPORE, September 17 (Reuters): The World Health Organisation said that more than 170 countries had joined its global plan to distribute vaccines fairly around the world, but cautioned that a race to develop shots could lead to public fears about safety. Trials of a vaccine in Britain were paused earlier this month following an illness in a participant, while Russia has dismissed criticisms from Western experts warning against early use of its vaccine candidate. "We
  • 'Vaccine nationalism will prolong the pandemic': WHO's Tedros
    GENEVA, September 4 (Reuters): WHO Director-General Tedros Adhanom Ghebreyesus called for countries around the world to join forces to tackle the coronavirus on Friday, saying that "vaccine nationalism" would only slow the response to the pandemic. The WHO and GAVI vaccine alliance are leading a global vaccine allocation plan known as COVAX aimed at helping buy and distribute vaccination shots fairly. But some countries that have secured their own supplies through
  • Widespread COVID-19 vaccinations not expected until mid-2021: WHO
    GENEVA, September 4 (Reuters): The World Health Organization does not expect widespread vaccinations against COVID-19 until the middle of next year, a spokeswoman said on Friday, stressing the importance of rigorous checks on their effectiveness and safety. None of the candidate vaccines in advanced clinical trials so far has demonstrated a "clear signal" of efficacy at the level of at least 50% sought by the WHO, spokeswoman Margaret Harris said. Russia granted re
  • Lancet Study finds Russian vaccine safe, effective
    New Delhi, September 4 (PTI): The COVID-19 vaccine, Sputnik V, approved by Russia last month, has been shown to elicit antibody response with no serious adverse events in small human trials, according to preliminary results published in The Lancet journal on Friday. Results from early-phase non-randomised vaccine trials in a total of 76 people show that two formulations of the vaccine have a good safety profile detected over 42 days, and induce antibody responses in all participants
  • AstraZeneca Covid vax reaches Phase-3 trial in US
    New York, September 1 (IANS): The Covid-19 vaccine candidate developed by Oxford University in partnership with the UK-based global biopharmaceutical company AstraZeneca has reached Phase-3 trial in the US. The trial will enroll approximately 30,000 adult volunteers at 80 sites in the US to evaluate if the candidate vaccine, known as AZD1222, can prevent symptomatic Covid-19, the US National Institutes of Health (NIH) said on Monday. "Positive results from preclinical resear